Celltrion's biosimilar Herzuma approved in Australia
SEOUL, Aug. 2 (Yonhap) -- South Korean biopharmaceutical firm Celltrion Inc. said Thursday that its breast cancer biosimilar has been approved by Australia's regulatory body.
The Therapeutic Goods Administration approved the sale of Herzuma, a drug based on Herceptin -- which was originally developed by Swiss pharmaceutical giant Roche Holding, the company said.
Herzuma will soon be distributed in Australia for the treatment of people who have been diagnosed with early stages of metastatic breast cancer and metastatic gastric cancer in adults, Celltrion said.
Annual global sales of the mega-hit Herceptin stand at 8.1 trillion won (US$7.1 billion), with the annual sales in the Australian market hitting 134.1 billion won.
The company said it will discuss with Celltrion Healthcare, which handles Celltrion's overseas business, the exact date of the launch.
khj@yna.co.kr
(END)
-
(Yonhap Interview) Fintech startup AIM aims to bring professional wealth services to ordinary investors
-
N.K. leader declares victory in fight against COVID-19: state media
-
N. Korea appears to release border dam water without prior notice: official
-
7 dead, 6 missing in heaviest rainfall in 80 years
-
(2nd LD) 7 dead, 6 missing in heaviest rainfall in 80 years
-
(Yonhap Interview) Fintech startup AIM aims to bring professional wealth services to ordinary investors
-
7 dead, 6 missing in heaviest rainfall in 80 years
-
(5th LD) 8 dead, 7 missing in record rainfall in Seoul, surrounding areas
-
N. Korea appears to release border dam water without prior notice: official
-
(LEAD) 7 dead, 6 missing in heaviest rainfall in 80 years
-
(LEAD) Suspended ruling party chief again cries foul over leadership switch
-
Heavy rain-caused deaths this week rise to 14; 5 go missing
-
(LEAD) Ex-presidential candidate Lee wins more rounds of voting for new DP leadership
-
(LEAD) Another person who disappeared into manhole amid downpours found dead
-
N. Korea moves toward pre-pandemic normalcy after declaring victory in COVID-19 fight